MedTrace Logo

Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD

NCT02321241 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2018-07-02

No results posted yet for this study

Summary

The aim of the TITAN study is to describe the clinical practices of a cohort of patients with wAMD refractory to ranibizumab (persistence of intra-retinal and/or subretinal fluid) who switch to aflibercept after less than 12 months of ranibizumab treatment.

The study will be conducted in real-life conditions and will allow describing conditions of use of aflibercept in patients refractory to ranibizumab

Conditions

  • Wet Macular Degeneration

Interventions

DRUG

Aflibercept (EYLEA, BAY-86-5321)

1. st year: 3 monthly injections followed by 1 injection every two months 2. nd year and following: injection according the visual and anatomical results observed the 1st year

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2017-01-18
Completion
2017-08-18

Countries

  • France

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321241 on ClinicalTrials.gov